Compare UP & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UP | PYXS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.2M | 141.3M |
| IPO Year | 2020 | 2021 |
| Metric | UP | PYXS |
|---|---|---|
| Price | $3.13 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | 75.1K | ★ 963.4K |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | 3.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $736,495,000.00 | $13,858,000.00 |
| Revenue This Year | $193.34 | N/A |
| Revenue Next Year | $12.65 | $14,188.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $1.03 |
| 52 Week High | $10.09 | $5.55 |
| Indicator | UP | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 38.33 |
| Support Level | $0.47 | $1.59 |
| Resistance Level | $4.01 | $1.84 |
| Average True Range (ATR) | 0.22 | 0.13 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 37.74 | 44.85 |
Wheels Up Experience Inc is a provider of on-demand private aviation. The company offers a private aviation solution with a large and diverse aircraft fleet, delivered through a mix of charter solutions and its membership program that utilizes its controlled aircraft fleet and a network of safety-vetted charter operators. Through its partnership firm, it provides members and customers with an offering across private and premium commercial travel. It generates the majority of its revenue from member and customer flights through its membership program and charter solutions, as well as from membership fees and other activities and services, including group charter flights, cargo flights, and special missions. Geographically, the company generates maximum revenue from the United States.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.